Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Net Income

Bottom-line profit after all expenses, interest, and taxes.

Nyxoah S.A.NASDAQ: NYXH

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -€18.42M, compared with -€22.38M a year earlier. Trailing-twelve-month net income was -€86.12M.

Context

  • Net income amounted to 899.1% of revenue in FY2025, down 411.2 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -€44.46M (+50.6%) for the fiscal year ending Dec 2026, a step up from the -52.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€18.42M+21.7% QoQ
Last fiscal yearDec 2025
-€90.09M-52.1% YoY
LTMMar 2026
-€86.12M-23.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%-116.2%-133.9 pp
1 year-52.1%+50.6%+102.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
(90.09M) EUR
Year-over-year change
-52.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -23.5% is the 6th highest of 10, against a peer median of -16.3%.
  • Net income amounts to 527.8% of revenue for NYXH, versus a peer median of 64.4%.
NYXH Competitors
Net Income for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTMDUtah Medical Products, Inc.LTM Mar 2026$10.85M USD-16.3%-11.8%28.9%
KRMDKORU Medical Systems, Inc.LTM Mar 2026-$2.28M USD+57.0%—5.3%
STIMNeuronetics, Inc.LTM Mar 2026-$37.11M USD+23.5%—24.5%
OABIOmniAb, Inc.LTM Mar 2026-$54.28M USD+11.4%—187.7%
TARAProtara Therapeutics, Inc.LTM Mar 2026-$63.31M USD-39.4%——
PREPrenetics Global LimitedLTM Mar 2026-$71.04M USD-47.6%—62.5%
OSUROraSure Technologies, Inc.LTM Mar 2026-$75.07M USD-134.9%—66.4%
IVVDInvivyd, Inc.LTM Mar 2026-$77.6M USD+45.6%—138.9%
NYXHNyxoah S.A.LTM Mar 2026-€86.12M EUR-23.5%—527.8%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$111.13M USD-30.5%—17982.7%
Peer median (excluding NYXH) —-16.3%-11.8%64.4%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.